Published in Pharma Law Weekly, July 25th, 2006
This includes, formulation development, stability testing, metabolism, pharmacokinetics and toxicology studies. Drug substance manufacturing is being scaled to kilogram level to support GLP toxicology and phase I. The data from these studies will enable the company to submit an investigational new drug application (IND) and initiate phase I studies during 2007.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.